On July 23, Tempus AI rose 6.43% in pre-market trading, trading at $47.75/share, with turnover of $558,700. The rebound follows a period of selling pressure triggered by the company's announcement of a major acquisition.

On the news front, Tempus AI previously announced it would acquire cancer detection company Personalis at $16.25 per share in an all-stock transaction, with a total enterprise value of approximately $1.5 billion. The deal aims to integrate Personalis' NeXT Personal minimal residual disease (MRD) detection platform into Tempus AI's AI-driven precision oncology system. The stock initially fell over 6% on concerns about capital pressure and integration risks.

Subsequently, Needham issued a research note stating that the acquisition price is supported by Personalis' strong growth prospects, Medicare reimbursement progress, and a large MRD market opportunity. The brokerage noted the valuation of roughly 15.5 times estimated 2027 enterprise value-to-sales is warranted given the growth outlook, and that competing bids and antitrust concerns are unlikely. Market sentiment has gradually recovered, driving the stock's rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)